BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Blay JY, Serrano C, Heinrich MC, Zalcberg J, Bauer S, Gelderblom H, Schöffski P, Jones RL, Attia S, D'Amato G, Chi P, Reichardt P, Meade J, Shi K, Ruiz-Soto R, George S, von Mehren M. Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 2020;21:923-34. [PMID: 32511981 DOI: 10.1016/S1470-2045(20)30168-6] [Cited by in Crossref: 59] [Cited by in F6Publishing: 23] [Article Influence: 29.5] [Reference Citation Analysis]
Number Citing Articles
1 Cusano E, Wong C, Taguedong E, Vaska M, Abedin T, Nixon N, Karim S, Tang P, Heng DYC, Ezeife D. Impact of Value Frameworks on the Magnitude of Clinical Benefit: Evaluating a Decade of Randomized Trials for Systemic Therapy in Solid Malignancies. Curr Oncol 2021;28:4894-928. [PMID: 34898590 DOI: 10.3390/curroncol28060412] [Reference Citation Analysis]
2 Tan AC, Boggs DH, Lee EQ, Kim MM, Mehta MP, Khasraw M. Clinical Trial Eligibility Criteria and Recently Approved Cancer Therapies for Patients With Brain Metastases. Front Oncol 2021;11:780379. [PMID: 35047397 DOI: 10.3389/fonc.2021.780379] [Reference Citation Analysis]
3 Klug LR, Khosroyani HM, Kent JD, Heinrich MC. New treatment strategies for advanced-stage gastrointestinal stromal tumours. Nat Rev Clin Oncol 2022. [PMID: 35217782 DOI: 10.1038/s41571-022-00606-4] [Reference Citation Analysis]
4 Cao L, Zheng K, Liu Y, Song P, Wang C, Wang H, Wang N, Zhang S, Zhao Y. Identification of Novel Imatinib-Resistant Genes in Gastrointestinal Stromal Tumors. Front Genet 2022;13:878145. [DOI: 10.3389/fgene.2022.878145] [Reference Citation Analysis]
5 Klug LR, Corless CL, Heinrich MC. Inhibition of KIT Tyrosine Kinase Activity: Two Decades After the First Approval. J Clin Oncol 2021;39:1674-86. [PMID: 33797935 DOI: 10.1200/JCO.20.03245] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Lostes-Bardaji MJ, García-Illescas D, Valverde C, Serrano C. Ripretinib in gastrointestinal stromal tumor: the long-awaited step forward. Ther Adv Med Oncol 2021;13:1758835920986498. [PMID: 33473249 DOI: 10.1177/1758835920986498] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 van de Wal D, Elie M, Le Cesne A, Fumagalli E, den Hollander D, Jones RL, Marquina G, Steeghs N, van der Graaf WTA, Husson O. Health-Related Quality of Life and Side Effects in Gastrointestinal Stromal Tumor (GIST) Patients Treated with Tyrosine Kinase Inhibitors: A Systematic Review of the Literature. Cancers (Basel) 2022;14:1832. [PMID: 35406604 DOI: 10.3390/cancers14071832] [Reference Citation Analysis]
8 Cicenas J, Račienė A. Anti-Cancer Drugs Targeting Protein Kinases Approved by FDA in 2020. Cancers (Basel) 2021;13:947. [PMID: 33668248 DOI: 10.3390/cancers13050947] [Reference Citation Analysis]
9 Liao W, Xu H, Hutton D, Wu Q, Zhou K, Luo H, Lei W, Feng M, Yang Y, Wen F, Li Q. Cost-Effectiveness Analysis of Fourth- or Further-Line Ripretinib in Advanced Gastrointestinal Stromal Tumors. Front Oncol 2021;11:692005. [PMID: 34938653 DOI: 10.3389/fonc.2021.692005] [Reference Citation Analysis]
10 . Ripretinib for gastrointestinal stromal tumours. Aust Prescr 2021;44:112. [PMID: 34211252 DOI: 10.18773/austprescr.2021.025] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Feng C, Virparia R, Mui ET. Analysis of the Real-Time Oncology Review (RTOR) Pilot Program for Approvals of New Molecular Entities. Ther Innov Regul Sci 2021;55:881-8. [PMID: 33913098 DOI: 10.1007/s43441-021-00296-7] [Reference Citation Analysis]
12 Sugiyama Y, Sasaki M, Kouyama M, Tazaki T, Takahashi S, Nakamitsu A. Current treatment strategies and future perspectives for gastrointestinal stromal tumors. World J Gastrointest Pathophysiol 2022; 13(1): 15-33 [DOI: 10.4291/wjgp.v13.i1.15] [Reference Citation Analysis]
13 Kelly CM, Gutierrez Sainz L, Chi P. The management of metastatic GIST: current standard and investigational therapeutics. J Hematol Oncol. 2021;14:2. [PMID: 33402214 DOI: 10.1186/s13045-020-01026-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
14 Zhang X, Liang Y, Li Y, Yin J. Comparative Efficacy and Safety of Different Regimens of Advanced Gastrointestinal Stromal Tumors After Failure Prior Tyrosine Kinase Inhibitors: A Network Meta-Analysis. Adv Ther 2021;38:399-412. [PMID: 33131035 DOI: 10.1007/s12325-020-01545-1] [Reference Citation Analysis]
15 Vibert J, Watson S. The Molecular Biology of Soft Tissue Sarcomas: Current Knowledge and Future Perspectives. Cancers 2022;14:2548. [DOI: 10.3390/cancers14102548] [Reference Citation Analysis]
16 Qu H, Xu Z, Ren Y, Gong Z, Ju RH, Zhang F, Kang H, Xu Y, Chen X. Recent Advancements in the Treatment of Rectal Gastrointestinal Stromal Tumor: In Era of Imatinib. CMAR 2022;Volume 14:1141-52. [DOI: 10.2147/cmar.s352860] [Reference Citation Analysis]
17 Schmidt T, Ghadimi M, Fuchs HF, Bruns CJ. [Surgical and interdisciplinary treatment of gastrointestinal stromal tumors]. Chirurg 2021. [PMID: 34709443 DOI: 10.1007/s00104-021-01527-1] [Reference Citation Analysis]
18 Kyriazoglou A, Jespers P, Vandecavaye V, Mir O, Kasper B, Papai Z, Blay JY, Italiano A, Zaffaroni F, Litière S, Nzokirantevye A, Schöffski P. Exploratory analysis of tumor imaging in a Phase 2 trial with cabozantinib in gastrointestinal stromal tumor: lessons learned from study EORTC STBSG 1317 'CaboGIST'. Acta Oncol 2022;61:663-8. [PMID: 35481400 DOI: 10.1080/0284186X.2022.2068967] [Reference Citation Analysis]
19 Kayki-Mutlu G, Michel MC. A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2020. Naunyn Schmiedebergs Arch Pharmacol 2021;394:839-52. [PMID: 33864098 DOI: 10.1007/s00210-021-02085-3] [Reference Citation Analysis]
20 Cristina Mendonça Nogueira T, Vinicius Nora de Souza M. New FDA oncology small molecule drugs approvals in 2020: Mechanism of action and clinical applications. Bioorg Med Chem 2021;46:116340. [PMID: 34416511 DOI: 10.1016/j.bmc.2021.116340] [Reference Citation Analysis]
21 Italiano A. Next questions for the medical treatment of gastrointestinal stromal tumor. Curr Opin Oncol 2022. [PMID: 35730519 DOI: 10.1097/CCO.0000000000000845] [Reference Citation Analysis]
22 Senchak J, Ahr K, von Mehren M. Gastrointestinal Stromal Tumors: What Is the Best Sequence of TKIs? Curr Treat Options in Oncol . [DOI: 10.1007/s11864-022-00958-0] [Reference Citation Analysis]
23 Pantaleo MA, Heinrich MC, Italiano A, Valverde C, Schöffski P, Grignani G, Reyners AKL, Bauer S, Reichardt P, Stark D, Berhanu G, Brandt U, Stefanelli T, Gelderblom H. A multicenter, dose-finding, phase 1b study of imatinib in combination with alpelisib as third-line treatment in patients with advanced gastrointestinal stromal tumor. BMC Cancer 2022;22:511. [PMID: 35524239 DOI: 10.1186/s12885-022-09610-4] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Schaefer IM, DeMatteo RP, Serrano C. The GIST of Advances in Treatment of Advanced Gastrointestinal Stromal Tumor. Am Soc Clin Oncol Educ Book 2022;42:1-15. [PMID: 35522913 DOI: 10.1200/EDBK_351231] [Reference Citation Analysis]
25 Lemaître J, Watson S. [New drug approvals: Ripretinib for advanced gastrointestinal stromal tumors (GIST) in fourth or later-line therapy]. Bull Cancer 2022:S0007-4551(22)00017-0. [PMID: 35094842 DOI: 10.1016/j.bulcan.2022.01.002] [Reference Citation Analysis]
26 Ayala-Aguilera CC, Valero T, Lorente-Macías Á, Baillache DJ, Croke S, Unciti-Broceta A. Small Molecule Kinase Inhibitor Drugs (1995-2021): Medical Indication, Pharmacology, and Synthesis. J Med Chem 2021. [PMID: 34624192 DOI: 10.1021/acs.jmedchem.1c00963] [Reference Citation Analysis]
27 Chi P, Qin LX, Nguyen B, Kelly CM, D'Angelo SP, Dickson MA, Gounder MM, Keohan ML, Movva S, Nacev BA, Rosenbaum E, Thornton KA, Crago AM, Yoon S, Ulaner G, Yeh R, Martindale M, Phelan HT, Biniakewitz MD, Warda S, Lee CJ, Berger MF, Schultz ND, Singer S, Hwang S, Chen Y, Antonescu CR, Tap WD. Phase II Trial of Imatinib Plus Binimetinib in Patients With Treatment-Naive Advanced Gastrointestinal Stromal Tumor. J Clin Oncol 2022;:JCO2102029. [PMID: 35041493 DOI: 10.1200/JCO.21.02029] [Reference Citation Analysis]
28 Oliveras JM, Puig de la Bellacasa R, Estrada-Tejedor R, Teixidó J, Borrell JI. 1,6-Naphthyridin-2(1H)-ones: Synthesis and Biomedical Applications. Pharmaceuticals (Basel) 2021;14:1029. [PMID: 34681253 DOI: 10.3390/ph14101029] [Reference Citation Analysis]
29 Wagner AJ, Severson PL, Shields AF, Patnaik A, Chugh R, Tinoco G, Wu G, Nespi M, Lin J, Zhang Y, Ewing T, Habets G, Burton EA, Matusow B, Tsai J, Tsang G, Shellooe R, Carias H, Chan K, Rezaei H, Sanftner L, Marimuthu A, Spevak W, Ibrahim PN, Inokuchi K, Alcantar O, Michelson G, Tsiatis AC, Zhang C, Bollag G, Trent JC, Tap WD. Association of Combination of Conformation-Specific KIT Inhibitors With Clinical Benefit in Patients With Refractory Gastrointestinal Stromal Tumors: A Phase 1b/2a Nonrandomized Clinical Trial. JAMA Oncol 2021. [PMID: 34236401 DOI: 10.1001/jamaoncol.2021.2086] [Reference Citation Analysis]
30 Feng M, Yang Y, Liao W, Li Q. Cost-Effectiveness Analysis of Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumor: A Systematic Review. Front Public Health 2021;9:768765. [PMID: 35083189 DOI: 10.3389/fpubh.2021.768765] [Reference Citation Analysis]
31 Kozinova MT, Abalakov GA, Sharipova DV, Shimanovsky NL. Molecular-Genetic Basis of Gastrointestinal Stromal Tumor Personalized Therapy by Receptor Tyrosine Kinase Inhibitors (A Review). Pharm Chem J. [DOI: 10.1007/s11094-021-02419-8] [Reference Citation Analysis]
32 Brčić I, Argyropoulos A, Liegl-Atzwanger B. Update on Molecular Genetics of Gastrointestinal Stromal Tumors. Diagnostics (Basel) 2021;11:194. [PMID: 33525726 DOI: 10.3390/diagnostics11020194] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Patterson T, Li H, Chai J, Debruyns A, Simmons C, Hart J, Pollock P, Holloway CL, Truong PT, Feng X. Locoregional Treatments for Metastatic Gastrointestinal Stromal Tumor in British Columbia: A Retrospective Cohort Study from January 2008 to December 2017. Cancers (Basel) 2022;14:1477. [PMID: 35326632 DOI: 10.3390/cancers14061477] [Reference Citation Analysis]
34 Huang L, Jiang S, Shi Y. Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001-2020). J Hematol Oncol 2020;13:143. [PMID: 33109256 DOI: 10.1186/s13045-020-00977-0] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 10.5] [Reference Citation Analysis]
35 Zalcberg JR. Ripretinib for the treatment of advanced gastrointestinal stromal tumor. Therap Adv Gastroenterol 2021;14:17562848211008177. [PMID: 33948116 DOI: 10.1177/17562848211008177] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 Vallilas C, Sarantis P, Kyriazoglou A, Koustas E, Theocharis S, Papavassiliou AG, Karamouzis MV. Gastrointestinal Stromal Tumors (GISTs): Novel Therapeutic Strategies with Immunotherapy and Small Molecules. Int J Mol Sci 2021;22:E493. [PMID: 33419029 DOI: 10.3390/ijms22020493] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
37 Patel SR, Reichardt P. An updated review of the treatment landscape for advanced gastrointestinal stromal tumors. Cancer 2021;127:2187-95. [PMID: 33974733 DOI: 10.1002/cncr.33630] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
38 Li X, Shelton MJ, Wang J, Meade J, Ruiz-Soto R. Effects of CYP3A Inhibition, CYP3A Induction, and Gastric Acid Reduction on the Pharmacokinetics of Ripretinib, a Switch Control KIT Tyrosine Kinase Inhibitor. Clin Pharmacol Drug Dev 2022. [PMID: 35560823 DOI: 10.1002/cpdd.1110] [Reference Citation Analysis]
39 Janku F, Abdul Razak AR, Chi P, Heinrich MC, von Mehren M, Jones RL, Ganjoo K, Trent J, Gelderblom H, Somaiah N, Hu S, Rosen O, Su Y, Ruiz-Soto R, Gordon M, George S. Switch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib. J Clin Oncol 2020;38:3294-303. [PMID: 32804590 DOI: 10.1200/JCO.20.00522] [Cited by in Crossref: 19] [Cited by in F6Publishing: 10] [Article Influence: 9.5] [Reference Citation Analysis]
40 Farag S, Smith MJ, Fotiadis N, Constantinidou A, Jones RL. Revolutions in treatment options in gastrointestinal stromal tumours (GISTs): the latest updates. Curr Treat Options Oncol 2020;21:55. [PMID: 32462367 DOI: 10.1007/s11864-020-00754-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
41 Amirnasr A, Sleijfer S, Wiemer EAC. Non-Coding RNAs, a Novel Paradigm for the Management of Gastrointestinal Stromal Tumors. Int J Mol Sci 2020;21:E6975. [PMID: 32972022 DOI: 10.3390/ijms21186975] [Reference Citation Analysis]
42 George S, Jones RL, Bauer S, Kang YK, Schöffski P, Eskens F, Mir O, Cassier PA, Serrano C, Tap WD, Trent J, Rutkowski P, Patel S, Chawla SP, Meiri E, Gordon M, Zhou T, Roche M, Heinrich MC, von Mehren M. Avapritinib in Patients With Advanced Gastrointestinal Stromal Tumors Following at Least Three Prior Lines of Therapy. Oncologist 2021;26:e639-49. [PMID: 33453089 DOI: 10.1002/onco.13674] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
43 Serrano C, Bauer S. New Tyrosine Kinase Inhibitors for the Treatment of Gastrointestinal Stromal Tumors. Curr Oncol Rep. [DOI: 10.1007/s11912-021-01165-0] [Reference Citation Analysis]
44 Brinch CM, Aggerholm-Pedersen N, Hogdall E, Krarup-Hansen A. Medical Oncological Treatment for Patients with Gastrointestinal Stromal Tumour (GIST) - a Systematic Review. Crit Rev Oncol Hematol 2022;:103650. [PMID: 35283299 DOI: 10.1016/j.critrevonc.2022.103650] [Reference Citation Analysis]
45 Braunstein C, Sirveaux F, Kalbacher E, Aubry S, Delroeux D, Hubert P, Marie B, Meynard G, Mihai I, Chaigneau L. Humeral metastasis as the only recurrence of a 5-year resected gastrointestinal stromal tumor: a case report. J Med Case Rep 2021;15:428. [PMID: 34404447 DOI: 10.1186/s13256-021-02962-8] [Reference Citation Analysis]
46 Foo T, Goldstein D, Segelov E, Shapiro J, Pavlakis N, Desai J, Yip D, Zalcberg J, Price TJ, Nagrial A, Chantrill L, Burge M, Karapetis CS, Tebbutt N, Roy AC. The Management of Unresectable, Advanced Gastrointestinal Stromal Tumours. Target Oncol 2022. [PMID: 35290591 DOI: 10.1007/s11523-022-00869-y] [Reference Citation Analysis]
47 Dudzisz-Śledź M, Bylina E, Teterycz P, Rutkowski P. Treatment of Metastatic Gastrointestinal Stromal Tumors (GIST): A Focus on Older Patients. Drugs Aging 2021;38:375-96. [PMID: 33651369 DOI: 10.1007/s40266-021-00841-x] [Reference Citation Analysis]
48 Bay JO, Bouleuc C, Firmin N, Gandemer V, Magne N, Orbach D, Penel N, Rodrigues M, Thiery-Vuillemin A, Wislez M, L'Allemain G, Sabatier R, Robert J; comité de rédaction du Bulletin du Cancer. [A 2021 inventory in oncology news]. Bull Cancer 2021:S0007-4551(21)00578-6. [PMID: 34980367 DOI: 10.1016/j.bulcan.2021.12.003] [Reference Citation Analysis]
49 Arifi S. Personalised pharmacotherapy options for soft tissue sarcomas. Expert Review of Precision Medicine and Drug Development 2022;7:17-28. [DOI: 10.1080/23808993.2022.2038562] [Reference Citation Analysis]
50 Bauer S, George S, von Mehren M, Heinrich MC. Early and Next-Generation KIT/PDGFRA Kinase Inhibitors and the Future of Treatment for Advanced Gastrointestinal Stromal Tumor. Front Oncol 2021;11:672500. [PMID: 34322383 DOI: 10.3389/fonc.2021.672500] [Reference Citation Analysis]
51 Nishida T, Doi T. A new approach to refractory gastrointestinal stromal tumours with diverse acquired mutations. Lancet Oncol 2020;21:864-5. [PMID: 32511982 DOI: 10.1016/S1470-2045(20)30209-6] [Reference Citation Analysis]
52 Goebel GL, Qiu X, Wu P. Kinase-targeting small-molecule inhibitors and emerging bifunctional molecules. Trends Pharmacol Sci 2022:S0165-6147(22)00086-4. [PMID: 35589447 DOI: 10.1016/j.tips.2022.04.006] [Reference Citation Analysis]
53 Gheorghe G, Bacalbasa N, Ceobanu G, Ilie M, Enache V, Constantinescu G, Bungau S, Diaconu CC. Gastrointestinal Stromal Tumors-A Mini Review. J Pers Med 2021;11:694. [PMID: 34442339 DOI: 10.3390/jpm11080694] [Reference Citation Analysis]
54 Huang S, Guo X, Xia Y, Ding L, Zhai E, Chen S, He Y, Cai S, Zhang X. Genotyping guided ripretinib directly after the progression of first-line imatinib therapy in advanced gastrointestinal stromal tumor: a case report. Ann Transl Med 2022;10:118. [PMID: 35282043 DOI: 10.21037/atm-21-6960] [Reference Citation Analysis]
55 Roulleaux Dugage M, Jones RL, Trent J, Champiat S, Dumont S. Beyond the Driver Mutation: Immunotherapies in Gastrointestinal Stromal Tumors. Front Immunol 2021;12:715727. [PMID: 34489967 DOI: 10.3389/fimmu.2021.715727] [Reference Citation Analysis]
56 Esteban-Villarrubia J, Soto-Castillo JJ, Pozas J, San Román-Gil M, Orejana-Martín I, Torres-Jiménez J, Carrato A, Alonso-Gordoa T, Molina-Cerrillo J. Tyrosine Kinase Receptors in Oncology. Int J Mol Sci 2020;21:E8529. [PMID: 33198314 DOI: 10.3390/ijms21228529] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
57 Nishida T, Yoshinaga S, Takahashi T, Naito Y. Recent Progress and Challenges in the Diagnosis and Treatment of Gastrointestinal Stromal Tumors. Cancers (Basel) 2021;13:3158. [PMID: 34202544 DOI: 10.3390/cancers13133158] [Reference Citation Analysis]
58 Reichardt P, Pink D. [Treatment of soft tissue sarcomas including GIST - Update 2021]. Dtsch Med Wochenschr 2021;146:157-61. [PMID: 33513648 DOI: 10.1055/a-1170-7731] [Reference Citation Analysis]
59 Alharthi FA, Al-Zaqri N, Alsalme A, Al-Taleb A, Pooventhiran T, Thomas R, Rao DJ. Excited-state electronic properties, structural studies, noncovalent interactions, and inhibition of the novel severe acute respiratory syndrome coronavirus 2 proteins in Ripretinib by first-principle simulations. J Mol Liq 2021;324:115134. [PMID: 33390634 DOI: 10.1016/j.molliq.2020.115134] [Cited by in Crossref: 5] [Article Influence: 5.0] [Reference Citation Analysis]
60 Sharma AK, Kim TS, Bauer S, Sicklick JK. Gastrointestinal Stromal Tumor. Surgical Oncology Clinics of North America 2022. [DOI: 10.1016/j.soc.2022.03.007] [Reference Citation Analysis]